XJPX
4438
Market cap17mUSD
Oct 09, Last price
292.00JPY
1D
-8.46%
1Q
15.42%
IPO
-93.38%
Name
Welby Inc
Chart & performance
P/E
—
P/S
3.87
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.15%
Rev. gr., 5y
-5.97%
Revenues
636m
+20.39%
Net income
-540m
L-32.93%
CFO
-329m
L-45.42%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Tokyo, Japan, in 2011, Welby Inc. specializes in developing digital healthcare solutions aimed at enhancing patients' access to and engagement with medical services. The company's extensive portfolio addresses a wide array of health conditions, encompassing diabetes mellitus, lifestyle-related diseases, mental health disorders, autoimmune and neurological diseases, rare conditions, oncology, and pain management. Furthermore, Welby is active in medical data surveying and operates its signature platform, Welby My Carte.
Key people
Nobuya Nakano
Senior Executive Officer, Director of Sales & Business Creation · since 2024
Masashi Shintani
Chief Marketing Officer, Director of Marketing, Executive Officer
Tetsuya Hayashi
Executive Officer, Director of Service Development · since 2022
Takeru Hiki
Representative Director · since 2011
Akira Kawahara
Director · since 2024
Director · since 2016
Takeshi Yamamoto
Representative Director · since 2023
Taro Ishibashi
Independent Director · since 2018
Naoya Matsumoto
Independent Director · since 2016
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||